<DOC>
	<DOCNO>NCT00315016</DOCNO>
	<brief_summary>The purpose study determine whether eplerenone effective double dose ACE inhibitor reduce urinary protein ( albumin ) loss diabetes mellitus</brief_summary>
	<brief_title>Eplerenone , ACE Inhibition Albuminuria</brief_title>
	<detailed_description>In patient proteinuric renal disease renal function almost invariably deteriorates , independent original renal disease . It demonstrate rapidity renal function deterioration determine blood pressure proteinuria1 . Treatment modality low proteinuria general tend attenuate deterioration renal function . As , ACE-inhibitors prove particular value treatment patient proteinuria , since drug consistently low proteinuria . More recently , similar antiproteinuric effect describe angiotensin receptor blocker ( ARBs ) . Theoretically , ACE inhibitor may advantage ARBs supposed increase bradykinin level . Bradykinin also implicate development nephropathy mouse . About role human diabetic nephropathy data exist . The effect ACE inhibition ARBs complete , since addition either drug may improve albuminuria . This may explain insufficient dosage single drug therapy escape phenomenon . The latter amply describe ACE inhibitor . Especially chronic ACE inhibition angiotensin II level may near normal . This may lead persistent angiotensin II effect , among aldosterone stimulation . Even though investigator emphasize role renin-angiotensin system progressive renal injury , aldosterone receive little attention . However , profibrotic effect make aldosterone potentially important player field , even escape aldosterone treatment ACE-inhibitors ARBs . Moreover , addition theoretical consideration , evidence emerge mineralocorticoid receptor blockade spironolactone add ACE-inhibitors ARBs indeed additive , favourable effect proteinuria . These finding warrant search value agent albuminuria exploration mechanism mineralocorticoid blockade may exert beneficial effect . Primary aim : 1 . To study whether combination eplerenone standard dose ACE-inhibition additive effect albuminuria patient albuminuric nephropathy compare ACE-I alone , double dose ACE-inhibitor .</detailed_description>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Fosinopril</mesh_term>
	<criteria>document diabetic renal disease albuminuria &gt; 0.020 g/L , stable renal function ( i.e . increase serum creatinine &lt; 25 % / 6 month ) , creatinine clearance &gt; 40 ml/min/1.73 m2 , spite maximal ACEinhibition ( 40 mg fosinopril/day ) blood pressure &lt; 140/90 mm Hg ( baseline ) serum potassium &lt; 5.0 mmol/l ( baseline ) . use NSAID 's immunosuppressive drug use ARBs , intolerance ACE inhibition . use diuretic increase potassium triamterene , spironolactone eplerenone pregnancy rash cough one drug severe heart disease instable angina</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>albuminuria</keyword>
	<keyword>eplerenone</keyword>
	<keyword>ACE inhibition</keyword>
	<keyword>renal function</keyword>
	<keyword>endothelial function</keyword>
</DOC>